Black patients received less clinical trial information than white patients

October 29, 2012

A study comparing how physicians discuss clinical trials during clinical interactions with black patients versus white patients further confirms racial disparities in the quality of communication between physicians and patients.

Oncologists provided black patients with less information overall about compared with white patients, according to data presented at the Fifth AACR Conference on The Science of Cancer Health Disparities, held Oct. 27-30, 2012.

"Minority patients tend to receive less information, which could, in part, explain under-enrollment by minorities in clinical ," said Susan Eggly, Ph.D., associate professor of oncology in the Population Studies and Disparities Program at Wayne State University School of Medicine and the Barbara Ann Karmanos Cancer Institute in Detroit, Mich. "These disparities could also lead to being enrolled in trials without fully understanding the purpose of the trial and the potential risks of participation."

Eggly and colleagues examined 22 video-recorded interactions between oncologists and patients during which a clinical trial was offered. Patients were matched by cancer type and . Half of the video-recorded interactions were with black patients and the other half were with white patients. Researchers used linguistic discourse analytical methods to examine several aspects of the interactions, including overall discussion of clinical trials and the five basic elements of consent: purpose, risks, benefits, alternatives to participating and the voluntary nature of trial participation.

Data revealed that clinical trial interactions with black patients were shorter overall and included less discussion of clinical trials compared with interactions with white patients. Key aspects of consent were also discussed less with black patients than with white patients, especially the purpose of the trial and risks of participation. However, the researchers found that oncologists spoke more about voluntary participation with black patients than with white patients.

Previous research by Eggly and colleagues showed that tended to ask fewer questions and they trusted their doctors less than did. In addition, physician biases affected the quality of communication, which Eggly believes may also account for the differences found in this study.

"Taking a close look at interactions and the language used can help us to identify patterns of behavior and make the necessary improvements that may ultimately lead to decisions that are in the best interest of each patient," she said.

Explore further: Black patients more likely to be monitored for prescription drug abuse

Related Stories

Black patients more likely to be monitored for prescription drug abuse

May 10, 2011
(Medical Xpress) -- Despite studies that show that whites are more likely than blacks to misuse prescription pain medications, a new study reveals that blacks are significantly more likely than whites to be checked for potential ...

Psychoeducational intervention changes patient attitudes on clinical trials participation

June 13, 2012
Seeking ways to change cancer patients' perceptions and negative attitudes towards clinical trials participation, researchers at Moffitt Cancer Center conducted a study offering two different kinds of intervention to two ...

Lower income cancer patients less likely to be involved in clinical trials

June 3, 2012
Cancer patients with annual household incomes below $50,000 were less likely to participate in clinical trials than patients with annual incomes of $50,000 or higher, and were more likely to be concerned about how to pay ...

Recommended for you

Study prompts new ideas on cancers' origins

December 16, 2017
Rapidly dividing, yet aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer—a finding that could upend the way scientists think about the ...

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.